A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme

Journal of Clinical Neuroscience

Volumn 19, Issue 12, 2012, Pages 1636-1640

  Zhang, Guobin ^a   Huang, Shengyue ^b   Wang, Zhongcheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bevacizumab; Glioblastoma; Irinotecan; Meta analysis

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CONVULSION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RECURRENT GLIOBLASTOMA; THROMBOEMBOLISM;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; YOUNG ADULT;

EID: 84868304292     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2011.12.028     Document Type: Article

References (37)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
2. P.Y. Wen, and S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
3. X. Ma, Y. Lv, and J. Liu Survival analysis of 205 patients with glioblastoma multiforme: clinical characteristics, treatment and prognosis in China J Clin Neurosci 16 2009 1595 1598
4. W.K. Yung, R.E. Albright, and J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 2000 588 593
5. A. Salmaggi, M. Eoli, and S. Frigerio Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma J Neurooncol 62 2003 297 303
6. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
7. M.R. Horsman, and D.W. Siemann Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies Cancer Res 66 2006 11520 11539
8. R.K. Jain, E. di Tomaso, and D.G. Duda Angiogenesis in brain tumours Nat Rev Neurosci 8 2007 610 622
9. S. Bao, Q. Wu, and S. Sathornsumetee Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 2006 7843 7848
10. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
11. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
12. S.B. Wedam, J.A. Low, and S.X. Yang Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 2006 769 777
13. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon II Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 2007 1253 1259
14. M.M. Mrugala Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 72 2009 772 773 author reply 773-774
15. M.D. Prados, K. Lamborn, and W.K. Yung A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro Oncol 8 2006 189 193
16. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon II Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
17. F. Bokstein, S. Shpigel, and D.T. Blumenthal Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors Cancer 112 2008 2267 2273
18. H.S. Poulsen, K. Grunnet, and M. Sorensen Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours Acta Oncol 48 2009 52 58
19. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
20. R.M. Zuniga, R. Torcuator, and R. Jain Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 2009 329 336
21. M.C. Chamberlain, and S.K. Johnston Salvage therapy with single agent bevacizumab for recurrent glioblastoma J Neurooncol 96 2010 259 269
22. T.N. Kreisl, L. Kim, and K. Moore Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
23. S.A. Ali, W.M. McHayleh, and A. Ahmad Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases J Neurosurg 109 2008 268 272
24. M.R. Gilbert MWKA: RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM) [abstract] J Clin Oncol 27 2009 15s
25. T.Y. Kang, T. Jin, and H. Elinzano Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety J Neurooncol 89 2008 113 118
26. W. Chen, S. Delaloye, and D.H. Silverman Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 2007 4714 4721
27. M. Jansen, P.C. de Witt Hamer, and A.N. Witmer Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas Brain Res Brain Res Rev 45 2004 143 163
28. J. Dietrich, A.D. Norden, and P.Y. Wen Emerging antiangiogenic treatments for gliomas - efficacy and safety issues Curr Opin Neurol 21 2008 736 744
29. P.O. Sakariassen, L. Prestegarden, and J. Wang Angiogenesis-independent tumor growth mediated by stem-like cancer cells Proc Natl Acad Sci U S A 103 2006 16466 16471
30. R.K. Jain, D.G. Duda, and J.W. Clark Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat Clin Pract Oncol 3 2006 24 40
31. J.W. Henson, S. Ulmer, and G.J. Harris Brain tumor imaging in clinical trials AJNR Am J Neuroradiol 29 2008 419 424
32. A.M. Omuro, and J.Y. Delattre What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Curr Opin Neurol 21 2008 717 719
33. J.N. Jakobsen, B. Hasselbalch, and M.T. Stockhausen Irinotecan and bevacizumab in recurrent glioblastoma multiforme Expert Opin Pharmacother 12 2011 825 833
34. S.R. Nalluri, D. Chu, and R. Keresztes Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
35. X.F. Hang, W.S. Xu, and J.X. Wang Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials Eur J Clin Pharmacol 67 2011 613 623
36. S. Hapani, D. Chu, and S. Wu Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 2009 559 568
37. A.M. Omuro, and J.Y. Delattre Editorial: what is new in the treatment of gliomas? Curr Opin Neurol 20 2007 704 707